|
| ADR REPORT |
|
| Year : 2022 | Volume
: 68
| Issue : 3 | Page : 168-169 |
Levetiracetam-induced gingival hyperplasia
J James, J Jose, VA Gafoor
Department of Neurology, Government Medical College, Kozhikode, Kerala, India
Correspondence Address:
J Jose
Department of Neurology, Government Medical College, Kozhikode, Kerala
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpgm.jpgm_1059_21
Levetiracetam is a new generation antiseizure medication which binds to synaptic vesicle protein SV2A and inhibits the release of neurotransmitters. Gingival hyperplasia is a common side effect of conventional antiseizure medications like phenytoin, but very rare with the newer ones. A 14-year-old boy was started on levetiracetam 250 mg twice daily after a generalized seizure. Five days later he presented with gingival swelling and painful oral aphthae, without lymphadenopathy or systemic symptoms. Blood investigations were normal. After one-month of stopping the drug, the lesions cleared. This case highlights the importance of maintaining good oral hygiene and periodic dental review in patients on antiseizure medications.
[FULL TEXT] [PDF]*
|
